ACP-196

Phase 2Small molecule

AAcerta Pharma BV

ACP-196 is one of 156 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

155

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CancerActive, not recruiting

Bladder CancerActive, not recruiting

Mantle Cell LymphomaActive, not recruiting

Glioblastoma MultiformeActive, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Bladder CancerPhase 2

Active, not recruiting

Mantle Cell LymphomaPhase 2

Active, not recruiting

Glioblastoma MultiformePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

ACP-196

AAcerta Pharma BV

Phase 2

2 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 5

Chemotherapy Agents

Takeda

Preclinical

1 6

Active Comparator

Moderna

Preclinical

1 7

Sulfonylureas

Eli Lilly

Preclinical

1 8

Thiazolidinediones

Sanofi

Preclinical

1 9

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

1 10

Meglitinides

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Mantle Cell Lymphoma

NCT02213926

Clinical

Trials by Indication[1]

Pancreatic Cancer2 trials

ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer

Completed·AAcerta Pharma BV·Phase 2·NCT02362048·77 enrolled

Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer

Terminated·AAcerta Pharma BV·Phase 2·NCT02570711·3 enrolled

Interaction1 trial

A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196

Completed·AAcerta Pharma BV·Phase 1·NCT04914936·72 enrolled

Adult1 trial

A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

Completed·AAcerta Pharma BV·Phase 1·NCT04867980·48 enrolled

Bladder Cancer1 trial

Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer

Completed·AAcerta Pharma BV·Phase 2·NCT02351739·78 enrolled

Drug Interactions1 trial

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants

Completed·AAcerta Pharma BV·Phase 1·NCT04901923·59 enrolled

5 more indications

Glioblastoma Multiforme1 trial

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Active, not recruiting·AAcerta Pharma BV·Phase 1/2·NCT02586857·24 enrolled

Tics1 trial

A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With Omeprazole

Completed·AAcerta Pharma BV·Phase 1·NCT04876807·36 enrolled

Hepatic Insufficiency1 trial

A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196

Completed·AAcerta Pharma BV·Phase 1·NCT04867941·18 enrolled

Mantle Cell Lymphoma1 trial

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Active, not recruiting·AAcerta Pharma BV·Phase 2·NCT02213926·124 enrolled

Relapsed/Refractory1 trial

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Active, not recruiting·AAcerta Pharma BV·Phase 2·NCT02717611·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for ACP-196. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ACP-196 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ACP-196. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Acerta Pharma BV company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAcerta Pharma BV

ACP-196

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Pancreatic Cancer2 trials

Interaction1 trial

Adult1 trial

Bladder Cancer1 trial

Drug Interactions1 trial

Glioblastoma Multiforme1 trial

Tics1 trial

Hepatic Insufficiency1 trial

Mantle Cell Lymphoma1 trial

Relapsed/Refractory1 trial

References

Drug Info

Quick Facts

Related News